Cogent Biosciences completes PEAK trial enrollment and advances past interim futility analysis

Cogent Biosciences, Inc.

Phase 3 PEAK trial enrolled 413 GIST patients, exceeding target; top-line results expected by end of 2025.
Independent Data Monitoring Committee recommended continuing PEAK study after pre-planned interim futility analysis.
SUMMIT trial in NonAdvSM now expects to complete enrollment in Q1 2025, three months earlier than projected.
Darara Dibabu appointed VP of Marketing; granted inducement award of 100,000 stock options at $10.74 per share.
Bezuclastinib combination with sunitinib for second-line GIST is primary focus of registration-directed trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.